Quick Answer
Inhibrx Biosciences, Inc. reported Net Income Loss of -$140.06 million for the year ending 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -108.3% in Net Income Loss from 2024 to 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Net Income Loss has grown by 42.0%.
- Historical annual values: Fiscal year 2025: -$140.06 million | Fiscal year 2024: $1.69 billion | Fiscal year 2023: -$241.36 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: